newsfilter
← Latest News
GlobeNewswire·

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in